Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Gains from Sales and Divestitures: 2023-2025

Historic Gains from Sales and Divestitures for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Sep 2025 value amounting to $922,848.

  • Orchestra BioMed Holdings' Gains from Sales and Divestitures rose 538.31% to $922,848 in Q3 2025 from the same period last year, while for Sep 2025 it was $922,848, marking a year-over-year increase of 538.31%. This contributed to the annual value of $416,368 for FY2024, which is 415.37% up from last year.
  • Latest data reveals that Orchestra BioMed Holdings reported Gains from Sales and Divestitures of $922,848 as of Q3 2025, which was up 47.56% from $625,414 recorded in Q2 2025.
  • Orchestra BioMed Holdings' 5-year Gains from Sales and Divestitures high stood at $922,848 for Q3 2025, and its period low was $13,100 during Q1 2024.
  • Over the past 3 years, Orchestra BioMed Holdings' median Gains from Sales and Divestitures value was $112,684 (recorded in 2023), while the average stood at $253,482.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first slumped by 64.85% in 2024, then soared by 2,704.30% in 2025.
  • Orchestra BioMed Holdings' Gains from Sales and Divestitures (Quarterly) stood at $80,790 in 2023, then spiked by 415.37% to $416,368 in 2024, then soared by 538.31% to $922,848 in 2025.
  • Its Gains from Sales and Divestitures was $922,848 in Q3 2025, compared to $625,414 in Q2 2025 and $178,286 in Q1 2025.